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In animals, oral administration of the cholera toxin B (CTB) subunit conjugated to the autoantigen insulin enhances the speciﬁc
immune-unresponsive state. This is called oral tolerance and is capable of suppressing autoimmune type 1 diabetes (T1D).
However, the process by which the CTB-insulin (CTB-INS) protein works as a therapy for T1D in vivo remains unclear. Here,
we successfully expressed a green ﬂuorescent protein- (GFP-) tagged CTB-Ins (CTB-Ins-GFP) fusion protein in silkworms in a
pentameric form that retained the native ability to activate the mechanism. Oral administration of the CTB-Ins-GFP protein
induced special tolerance, delayed the development of diabetic symptoms, and suppressed T1D onset in nonobese diabetic (NOD)
mice. Moreover, it increased the numbers of CD4+CD25+Foxp3+ T regulatory (Treg) cells in peripheral lymph tissues and aﬀected
the biological activity of spleen cells. This study demonstrated that the CTB-Ins-GFP protein produced in silkworms acted as an
oral protein vaccine, inducing immunological tolerance involving CD4+CD25+Foxp3+ Treg cells in treating T1D.
1.Introduction
Oral tolerance refers to the physiological response of an
organism remaining in a state of speciﬁc immunological
unresponsiveness to some food antigens that is orally
administered [1]. Data indicate that this can be used to
treatautoimmunediseases,liketype1diabetes(T1D),which
has speciﬁc postulated autoantigens, such as insulin and
glutamic acid decarboxylase 65 [2–5]. Indeed, in animal
models, oral administration of tissue-speciﬁc antigen insulin
w a sa b l et op r e v e n tT 1 D[ 6]. However, a major problem
remains to be solved if oral tolerance is employed to
treat human autoimmune diseases: how to obtain suﬃcient
amounts of autoantigens for repeated oral administration
because humans have an enormous intestinal absorptive
surface area. Thus, the eﬀective use of oral tolerance to treat
autoimmune diseases may depend on the use of mucosal
adjuvants to enhance eﬃcacy.
As a mucosal carrier, the nontoxic cholera toxin B sub-
unit (CTB) is conjugated to autoantigens for the induction
of oral tolerance [7]. It has also been demonstrated in
similar systems [8–10] that conjugating antigen to CTB
can increase eﬃciency and thus reduce eﬀective antigen
doses. The therapeutic applications of CTB-mediated oral
tolerance, as demonstrated in animal models, include the
prevention and treatment of T-cell-mediated autoimmune
diabetes [11].
The intestinal mucosa is the central location for the
induction of oral tolerance [12]. Orally administrated,
cholera toxin (CT), a potent mucosal modulator, induces
the appearance of cells that share some common traits with
Peyer’s patch (PP) M-cells in mice [13]. Glycoprotein 2
o nM - c e l l ss e r v e sa sat r a n s c y t o t i cr e c e p t o rf o rm u c o s a l
antigens [14]. Additionally, it has been shown that dendritic
cells (DCs) in the gut-associated lymphoid tissue (GALT)
take up antigen and transfer it to T cells to generate
Treg cells in oral tolerance-treated arthritic mice [15].
Sublingual administration of CTB-conjugated antigen to
B-cell-deﬁcient mice sharply reduced CD4+CD25+Foxp3+
Treg cells compared with the wild type [16, 17]. Together,2 Clinical and Developmental Immunology
Table 1: Five primers synthesized for the construction of the fusion proteins.
No. Sequence Length
P1 5 -CGGGATCCATGATTAAATTAAAATTTGG-3  (BamHI) 28bp
P2 5 -GGGGCCGGGGCCGTTGCAGTAGTTCTCCA-3  (GPGP) 29bp
P3 5 -GGGGCCGGGGCCATTTGCCATACTAAT-3  (GPGP) 27bp
P4 5 -GGCCCCCGGCCCCGTGAGCAAGGGCGAGGA-3  (GPGP) 29bp
P5 5 -TGCTCGAGTTACTTGTACAGCTCGTCC-3  (XhoI) 27bp
The italics in P1 and P5 indicate BamHI and XhoI restriction endonuclease sites, respectively. Bold type indicates the linker peptide (GPGP).
these ﬁndings suggest that the regulatory T cells elicited by
mucosal immunization with CTB conjugated peptides are
unique and distinct from those that arise from spontaneous
endogenous priming. This protein vaccine therapy may be
useful in treating autoimmune diseases.
T1D is a spontaneous autoimmune disease associated
with the pancreas in which damage to the insulin-producing
β-cells disturbs glucose metabolism and leads to a series of
complications [18]. The autoantigen insulin conjugated to
CTB produced in silkworms can induce oral tolerance, pro-
tecting against T1D in NOD mice [19]. Using the silkworm
asa“bioreactor”toobtainlargeamountsofproteinsthrough
the insect baculovirus expression system (BES) has many
merits [20, 21]. As the green ﬂuorescent protein (GFP) is
widelyused torevealintestinal epithelial immunoreaction by
tagging antibodies or microorganisms [13, 14], we expressed
a GFP-tagged CTB-Ins (CTB-Ins-GFP) protein by a Bac-to-
Bac silkworm BES in this study. We found that the CTB-
Ins-GFP fusion protein was eﬃciently produced in both
BmN cells and silkworms and possessed the functional
characteristics of native CTB. Oral administration of the
protein was capable of inducing speciﬁc immune tolerance,
delaying diabetes symptoms, and suppressing T1D onset in
NOD mice. The speciﬁc tolerance could increase the Foxp3+
regulatoryT cell proportions in peripheral lymph tissues and
suppress the biological functions of spleen lymphocytes in
mice. This silkworm-produced active CTB-Ins-GFP protein,
administered as a vaccine protein, was able to induce insulin
speciﬁc oral tolerance, which is related to increased Treg cells
in the treatment of T1D.
2.MaterialandMethods
2.1. Reagents, Cell Lines, Silkworms, and Mice. DNA mani-
pulation and PCR ampliﬁcation kits were purchased
from TaKaRa Biomedicals (Japan). The rabbit anticholera
toxin primary serum, bacterial CTB peptides, and mono-
sialoganglioside-GM1 were from Sigma-Aldrich (USA). A
mouse regulatory T-cell staining kit was obtained from
eBioscience (USA). Transwell chambers (∅=8μm) were
purchased from Corning Incorporated (USA). The silkworm
BmN cells were cultured in TC-100 medium (Gibco-BRL,
USA) containing 10% fetal calf serum (Gibco-BRL, USA)
and 50μg/mL gentamycin at 27◦C. Fifth-instar silkworm
B. mori larvae (Jingsong × Haoyue, Showa) were fed fresh
mulberry leaves and reared under a photoperiod schedule
of 12-h light and 12-h darkness at 25 ± 1◦C. Female
nonobese diabetic (NOD) mice and NOD severe combined
immunodeﬁcient (NOD/SCID) mice were purchased from
Shanghai Laboratory Animal Center, Chinese Academy of
Sciences (SLAC, CAS, China), and housed at the central
animal facility, where they were screened for bacterial and
viral pathogens.
2.2. Construction of Recombinant Bacmid Vectors. Five
primers were designed prior to the construction of the
CTB-GFP and CTB-Ins-GFP fusion genes (Table 1). Using
the recombinant PAK-CTB-INS plasmid and the pEGFP
plasmid [22] as templates, the CTB-GFP and CTB-Ins-GFP
fusion genes were ampliﬁed by splice overlap extension
PCR (SOE-PCR), identiﬁed, and subcloned into the donor
pFastBac1 plasmid. Then, the recombinant bacmid vectors
were constructed and veriﬁed by PCR identiﬁcation and
fragment sequencing.
2.3. Acquisition of Recombinant Baculovirus in BmN Cells. A
subconﬂuent monolayer of BmN cells was transfected with
the recombinant bacmid vectors using Lipofectamine 2000
(Invitrogen, USA). The recombinant virus was generated
in the transfected BmN cells after 3–5 days and veriﬁed
by detection of green ﬂuorescent light under a ﬂuorescent
microscope (Nikon, Japan). Viral genomic DNA was then
extracted using the Wizard genomic DNA puriﬁcation kit
(Promega, USA) and identiﬁed by PCR ampliﬁcation and
fragment sequencing. Prior to the next viral infection for
fusion protein expression, the dilution of the recombinant
virus was calculated using the Reed-Muench method.
2.4. Expression and Collection of the Fusion Proteins. BmN
cells (4 × 106) were infected by BmNPV CTB-GFP and
BmNPV CTB-Ins-GFP at MOI = 10 and collected at 2–7
days after infection. Harvested BmN cells were suspended in
0.5mL phosphate-buﬀered Saline (PBS) and lysed by gentle
sonication several times on ice. They were centrifuged and
the supernatant removed and stored at −20◦C. The ﬁfth-
instar silkworm larvae were needle inoculated with the viral
solutions (1 × 107 pfu/mL) into their body cavities. The
hemolymph of the larvae were collected at 2–7 days after
inoculation, centrifuged to remove insoluble impurities, and
stored at −20◦C.
2.5. Western Blot and ELISA Assay. To detect the expression
of monomeric or pentameric fusion proteins, the cell-
lysed supernatants or hemolymph samples were diluted and
separated by 12% SDS-PAGE. Samples were either boiled or
loaded directly on the gel. The separated protein bands wereClinical and Developmental Immunology 3
then transferred to a nitrocellulose (NC) ﬁlter membrane.
Detection of the immunoreaction was performed with an
enhanced chemiluminescence (ECL) Western blotting kit
(BiologicaclIndustries,Israel).Rabbitanticholeratoxinanti-
serum (Sigma, USA) and rabbit anti-GFP primary antibody
(Epitomics, USA) were used for the immunoreactions.
A semiquantitative ELISA was used to investigate the
expression level of the fusion protein. A 96-well microtiter
plate was loaded with dilutions of the cell-lysed supernatant
(1:20–1:100) or hemolymph (1:500–1:2000) in bicarbon-
ate buﬀer, pH 9.6 (15mM Na2CO3,3 5 m MN a H C O 3)a t
4◦C overnight. The plate was blocked with 1% BSA at
37◦C for 1h and then washed with PBS containing 0.05%
Tween-20 (PBST). A 1:5000 dilution of anticholera toxin
antiserum in 1% BSA was added at 37◦C for 2h. It was then
washed with PBST and incubated with a 1:10000 dilution
of antirabbit IgG conjugated with horseradish peroxidase
at 37◦C for 40min. Finally, the chromogenic substrate O-
phenylenediamine was added at 37◦Cf o r3 0m i nt od e v e l o p
color and 2M H2SO4 (50μL/well) was added to stop the
reaction. The absorbance at 492nm was measured in a
Labsystems Multiscan MS ELISA plate reader (Labsystems,
Finland). Serial dilutions of bacterial CTB (Sigma, USA)
were used to generate the standard curve to calculate the
results.
2.6. GM1 Ganglioside-Binding Assay. A GM1-ELISA was
performed to detect the aﬃnity of silkworm-derived fusion
proteins for GM1 ganglioside. The microtiter plates were
coated with monosialoganglioside-GM1 (Sigma, USA) by
incubating the plates with 50μL / w e l lo fG M 1i nm e t h a n o l
at 4◦C overnight. The wells were then blocked with BSA
solution, and the dilutions of hemolymph were added. The
remainder of the procedure was identical to the semiquan-
titative ELISA assay described above. The same dilutions of
normal hemolymph and serial dilutions of bacterial CTB
were used as a negative control and to generate the standard
curve, respectively.
2.7. Induction of Oral Tolerance. Five-week-old female NOD
mice were divided into four groups and fed with Saline,
hemolymph synthesized CTB-GFP protein, CTB-Ins-GFP
protein, or CTB-INS protein. Beginning at 5 weeks of age,
the mice were fed an equal amount of hemolymph (about
100–300μL) every other day until 10 weeks of age. Each
feeding of hemolymph delivered approximately 50μg of the
corresponding fusion proteins. The animals were sacriﬁced
at 10 weeks of age for antibody titer assays and pancreatic
islet histopathological analysis.
2.8. Pancreatic Islet Histopathological Analysis. To evaluate
insulitis in experimental NOD mice, the extent of lympho-
cyte inﬁltration in the islets was measured. At 10 weeks
of age, six mice in each group were sacriﬁced and the
pancreas removed. Each pancreas was ﬁxed in PBS-buﬀered
paraformaldehyde, embedded in paraﬃn, cut into 5μm
sections,andstainedwithhematoxylinandeosin.Thedegree
ofinsulitiswasevaluatedusingastandardizedscoringsystem
with two independent observers using a semiquantitative
scale ranging from 0 to 4: 0, normal islet with no sign of T-
cell inﬁltration, 1, focal peri-islet T-cell inﬁltration, 2, more
extensive peri-islet inﬁltration but with lymphocytes less
than one-third of the islet area, 3, intraislet T-cell inﬁltration
in one-third to one-half of the islet area, and 4, extensive
intraislet inﬂammation involving more than half of the islet
area. At least 20 islets were scored for each animal.
2.9.AssessmentofDiabetes. Incidencesofdiabeteswerecom-
pared among mice fed the CTB-INS, CTB-Ins-GFP, or CTB-
GFP fusion proteins or Saline. The feeding schedule was
the same as mentioned above and continued for 30 weeks.
Starting at 10 weeks of age, the development of diabetes
was monitored and conﬁrmed by measuring blood glucose
using the ACCU-CHEK III system (Roche Diagnostics Ltd.,
Shanghai, China). A mouse with a blood glucose level above
16.7mM for 2 consecutive weeks was considered diabetic.
2.10. Gut Mucosal Binding Assay. Mice were anesthetized
withetherandkeptwarmona37◦Cwarmingpadduringthe
assay. Silkworm-derived CTB-GFP or CTB-Ins-GFP fusion
proteins were injected into the ligated intestinal loops. After
incubation for 30–60min, the mice were sacriﬁced and
part of the intestinal loops (about 5mm) was excised [14].
After washing, 8μm frozen sections of the specimens were
prepared. The locations of the proteins were veriﬁed by
ﬂuorescent microscopy.
2.11. Quantiﬁcation of Serum Antibody Subtypes. Treated
NOD mouse serum was quantiﬁed for anti-CTB and anti-
insulinantibodysubtypeusingELISA.Humaninsulin(Novo
Nordisk) or bacterial CTB were used as the well-coating
antigens and after blocking, serial dilutions of pooled sera
were added to the coated microtiter plate wells. Horseradish
peroxidase-conjugated antimouse IgG1, IgG2a, IgA, or IgE
antibody (SABC, China) was usedas the secondary antibody.
The absorption value was measured as described above. The
titer was deﬁned as the reciprocal of the highest dilution of
the sample giving an absorption signal above background,
and was individually determined for each sample.
2.12. Cytometric Analysis of Treg Cell Flow. Lymphocytes
in the spleen, intestinal lymph nodes, and blood of 10-
week-old treated NOD mice were obtained with the help
of mouse lymphocyte separation medium (Dakewe Biotech
Company, Limited, China). Then, the assay was performed
with a mouse regulatory T-cell staining kit, which contains
FITC-antiCD4 antibody, PE-antiCD25 antibody, and PE-
cy5-antiFoxp3 antibody, according to the manufacturer s
protocol. Proportions of Treg cells in the lymph tissues were
analyzed by ﬂow cytometric analysis of lymphocyte pheno-
typic markers with a FACScan ﬂow cytometer (Beckman
Coulter, USA).
2.13. Spleen Lymphocyte BrdU Label Analysis. Spleen lym-
phocyteswereculturedwith10μM5-bromo-2-deoxyuridine
for 1 day to label the proliferated cells as in a previous
study [23] .T h e yw e r et h e nﬁ x e da n dt r e a t e dw i t hT r i t o nX -
100 and H2O2, denatured with HCl, and neutralized with4 Clinical and Developmental Immunology
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Figure 1: Schematic structure of the CTB-Ins-GFP fusion gene. AcMNPV Ph-Pro: Autographa californica multiple nuclear polyhedrosis
virus polyhedrin promoter, CTB: cholera toxin B subunit, L: linker peptide (GPGP), InsA: human insulin subunit A, InsB: human insulin
subunit B (InsA and InsB are linked by mini-C peptide (RRGSKR)), GFP: green ﬂuorescent protein, and LB and RB: left and right border,
respectively, of the donor vector pFastBac1.
boric acid, all at room temperature. Following blocking, the
cells were treated with mouse anti-BrdU antibody (Boster,
China) then incubated with biotin-labeled antimouse IgG
antibody. Next, ABC compound was added to the cells. DAB
was used to develop the corresponding brown color with
hematoxylin used as a counterstain. Samples were analyzed
using a microscope at 400x.
2.14. Spleen Lymphocyte Transwell Assay. Spleen lympho-
cytes (1 × 105) were isolated from NOD mice, and cultured
in the upper chamber of 24-well Transwell plates with RPMI
1640 serum-free medium. IL2 was added in the normal
culture medium (150IU/mL) and placed in the bottom
chamber and the cells were cultured for about 14h at 37◦C
with 5% CO2. Next, the cells were ﬁxed and stained with
crystal violet solution after the cells upon the chamber were
clear. Samples were analyzed using a microscope at 400x.
2.15. Adoptive Transfer of Diabetes. Splenocytes from 10-
week-old NOD mice fed CTB-Ins-GFP fusion proteins were
assessed for the capacity to suppress the diabetogenic activity
of splenocytes taken from an acutely diabetic donor. Brieﬂy,
splenocytes (1 × 107 cells) from the three treated groups, but
not Saline-fed NOD mice, were mixed with splenocytes (1
× 107 cells) from newly diabetic NOD mice and given by
intravenous injection (i.v.) into the tail veins of 6–8-week-
old NOD/SCID mice. Mice receiving only 1 × 107 diabetic
splenocytes were used as a control. Recipient mice were
monitored for the development of diabetes for 15 weeks.
2.16. Statistical Analysis. Survival analyses with Kaplan-
Meier estimates were used to evaluate the diﬀerence in
diabetes incidence among the NOD mice groups. Results
were otherwise analyzed by using t-tests or ANOVA for
multiple comparisons. A P value of less than .05 was
considered to indicate statistical signiﬁcance in all cases.
3. Results
3.1. Construction and Identiﬁcation of the Recombinant
BmNPV CTB-Ins-GFP. Using pEGFP, PAK-CTB-INS, and
ﬁve primers, we obtained the GFP, CTB, and CTB-Ins genes
by traditional PCR. Using the SOE-PCR method, the GFP
gene was anchored separately at the 3 -end of the CTB
and CTB-Ins genes to form the CTB-GFP and CTB-Ins-
GFP fusion genes, respectively. A ﬂexible hinge tetrapeptide
(GPGP) was introduced between the two peptides to main-
tain the natural conformation of CTB/CTB-Ins and GFP
(Figure 1). The segments were conﬁrmed by autosequencing
and then subcloned into the pFastBac1 vector. Results of the
enzyme digestion, PCR ampliﬁcation, full-length nucleotide
sequencing, and deduced amino acid sequences showed the
fusion genes were exactly inserted into the pFastBac1 vector
(data not shown). Then, they were transformed into the
E. coli host strain DH10α (competent cells) to generate
recombinant bacmid vectors. PCR results showed that the
recombinant bacmid vectors were successfully constructed
(data not shown). The BmN cells were transfected by the
recombinant bacmid vectors to obtain recombinant viruses.
Viral genomic DNA was extracted and recombined by PCR
ampliﬁcation (data not shown). According to the Reed-
Muench formula, the dilutions of the recombinant viruses
were 1.17 × 109 for BmNPV CTB-Ins-GFP and 5.62 × 109
for BmNPV CTB-GFP (data not shown).
3.2. High Expression of the CTB-Ins-GFP Recombinant Pro-
tein. When infected with the recombinant virus, BmN cells
and silkworm larvae showed virus infection symptoms and
started to produce CTB-GFP and CTB-Ins-GFP fusion
proteins in the cytoplasm and body cavity, respectively
(Figure 2(a)). The presence of the proteins was determined
by Western blot analysis with anti-CTB or -GFP antibodies
(Figure 2(b)). We found that the oligomeric fusion pro-
teins (CTB-GFP protein ∼195kDa; CTB-Ins-GFP protein
∼240kDa) were dissociated into monomers by boiling and
subsequently migrated as a speciﬁc band with an apparent
molecular weight (CTB-GFP protein ∼39kDa; CTB-Ins-
GFP protein ∼48kDa), with normal samples as negative
controls. No immunospeciﬁc signal corresponded in molec-
ular mass to the CTB-GFP or CTB-Ins-GFP fusion proteins
in normal cells or normal hemolymph samples. Moreover,
the ELISA results showed that the highest detectable level
of the CTB-GFP and CTB-Ins-GFP fusion proteins yielded
by BmN cells was 0.037mg/2 × 106 cells on the 6th day
after infection (Figure 2(c)). In the infected silkworm larvae,
the recombinant fusion proteins were eﬃciently expressedClinical and Developmental Immunology 5
(a)
Boiled
N 12
Unboiled
N1 2
118kD
90kD
50kD
34kD
Boiled
M N12
Unboiled
N12
BmN cells
Silkworm
118kD
90kD
50kD
(b)
0
0.03
0.06
0.09
2d 3d 4d 5d 6d 7d
(
m
g
/
m
L
)
Normal
CTB-Ins-GFP
CTB-GFP
0
0.25
0.5
0.75
2d 3d 4d 5d 6d 7d
CTB-Ins-GFP
CTB-GFP
(
m
g
/
m
L
)
Protein expression in BmN cells (days) Protein expression in silkworm (days)
(c)
Figure 2: Identiﬁcation of the expressed fusion proteins. (a) Fusion protein expression in BmN cells and silkworm B. mori ﬁfth-instar
larvae. Left to right: BmNPV CTB-GFP or BmNPV CTB-Ins-GFP 5 days after infection under normal light, blue light, and overlapped.
Magniﬁcation, 200x. Lower: B. mori ﬁfth-instar normal larvae and larvae infected with recombinant viruses 5 days after infection under
ultraviolet radiation. (b) Western blot analysis of fusion protein expression. Lane N: control, lane 1: CTB-Ins-GFP protein, lane 2: CTB-
GFP protein. GFP antibody was used as the primary antibody. Silkworm: lane M: molecular weight standard, lane N: normal sample, lane
1: CTB-Ins-GFP protein, lane 2: CTB-GFP protein. Anti-CTB serum was used as the primary antibody. The arrows denote the pentamers
(∼240,195kDa)andmonomers(∼48,39kDa)oftheCTB-Ins-GFPandCTB-GFPproteins.(c)ELISAsemiquantiﬁcationanalysisofprotein
expression. Concentrations on days after infection were calculated according to the standard curve of bacterial CTB. Data are presented as
the mean concentration ± SD on each day. The experiment was repeated twice.6 Clinical and Developmental Immunology
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Figure 3: GM1 aﬃnity assay. (a) Reactivity of the CTB-Ins-GFP protein with the GM1 ganglioside and a native bacterial CTB control. (b)
Boiling induced pentamer dissociation into monomers. Approximately equal amounts of the three diﬀerent samples indicated were used to
measure A492 signal levels. Data represent the mean A492 values ± SD of each sample. The experiment was repeated twice.
and released into the larval hemolymph. On the 6th day
after infection, the maximum amount of fusion protein
in the hemolymph reached 0.58mg/mL with an average
of 0.4mL hemolymph per larva (Figure 2(c)). The results
demonstrated that the silkworm is a powerful “bioreactor”
for protein production.
3.3. Strong Aﬃnity of the Recombinant Protein for the
GM1 Ganglioside. The CTB-based protein in its natural
conformation forms a pentameric structure and possesses an
aﬃnity for the GM1 ganglioside, so we used the GM1-ELISA
method with GM1 ganglioside as the capture molecule to
conﬁrmthespeciﬁcaﬃnityofthefusionprotein.Anincrease
in the concentration-speciﬁc absorption signal was observed
in contrast to the bacterial pentameric CTB standard curve,
indicating that the recombinant protein existed as pen-
tamers, because only pentameric protein binds to GM1 gan-
glioside (Figure 3(a)). However, the heat-treated protein lost
its aﬃnity for GM1 ganglioside (Figure 3(b)). The silkworm-
derived recombinant protein exhibited the biochemical and
antigenic properties of CTB necessary for the next study.
The GM1-binding ability also suggested proper folding of
the CTB-GFP and CTB-Ins-GFP molecules, resulting in a
functional pentameric structure.
3.4. Feeding of CTB-Ins-GFP Protein Reduces Insulitis and
Suppresses Diabetes. To investigate the impact on insulitis as
a result of feeding CTB-Ins-GFP protein to NOD mice, 5-
week-old female NOD mice were given larval hemolymph
containingrecombinantCTB-GFPorCTB-Ins-GFPproteins
or Saline, with a group fed hemolymph containing CTB-INS
as a positive control, until 10 weeks. Then, their pancreatic
tissues were collected and the islets individually scored for
insulitis. Representative pancreatic islets from animals fed
CTB-Ins-GFP or CTB-INS fusion proteins had insulitis
scores of 1 and 2 (Figure 4(a)(2), (3)), whereas animals
fed CTB-GFP or Saline had insulitis scores of 3 and 4
(Figure 4(a)(4)) with normal mice as a negative control
(Figure 4(a)(1)). The ANOVA test revealed a signiﬁcant
reduction of insulitis in mice fed CTB-Ins-GFP or CTB-
INS in contrast to the CTB-GFP or Saline groups (1.1 ±
0.3 and 1.4 ± 0.3 versus 2.9 ± 0.5 and 3.1 ± 0.6, resp.;
P< . 05; Figure 4(b)). No signiﬁcant diﬀerence in insulitis
scores was found in mice fed CTB-GFP or Saline. These
results showed the CTB-Ins-GFP protein synthesized by the
silkworm eﬀectively suppressed insulitis.
We then investigated whether long-term oral adminis-
tration of the CTB-Ins-GFP fusion protein could prevent
diabetes. Prediabetic female NOD mice were orally admin-
istered the CTB-Ins-GFP fusion protein from 5 to 35 weeks
of age with a CTB-INS protein-fed group as a control. In
the early stages, mice in all groups had normal appetites and
weight gains, and no apparent diﬀerence was observed (data
not shown). Then, the mice were found to have a decrease in
body weight and an increase in appetite (data not shown).
At 35 weeks of age, only 39% and 33% (7/18 and 6/18) of the
NOD mice that received CTB-INS (group 1) or CTB-Ins-
GFP (group 2) fusion protein developed diabetes compared
with 67% and 70% (12/18 and 7/10) of those fed the
CTB-GFP peptide (group 3) or Saline (group 4), respectively
(groups 1 and 2 versus groups 3 and 4, P = .0276; group 1
versus group 2, P = .9683; Figure 5). Although this resultClinical and Developmental Immunology 7
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Figure 4: Insulitis score analysis. (a) Representative histopathological pancreatic islets from normal mice or experimental NOD mice. (b)
Semiquantitative analysis of pancreatic islet insulitis score. Data are expressed as the mean score for each group ± SD. The ANOVA test
revealed a signiﬁcant reduction in insulitis in mice fed CTB-INS or CTB-Ins-GFP in contrast to the CTB-GFP or Saline group (1.1 ± 0.3 and
1.4 ± 0.3 versus 2.9 ± 0.5 and 3.1 ± 0.6, resp., P<. 05). No signiﬁcant diﬀerence in insulitis score was found in mice fed either CTB-GFP or
Saline. Six mice per group were tested in two separate experiments.
showed that feeding CTB-Ins-GFP fusion protein might not
totally suppress diabetes development in NOD mice, the
incidence of diabetes decreased markedly in the CTB-Ins-
GFP- and CTB-INS protein-fed groups, compared with the
CTB-GFP and Saline groups. The percentage of mice fed
CTB-GFP alone did not diﬀer signiﬁcantly from the Saline
control group. These results suggest that the CTB-Ins-GFP
fusion protein, orally administered, may oﬀer an alternative
approach to eﬀectively prevent or even treat diabetes.
3.5. Interaction between the Recombinant Protein and Gut
Mucosa. To verify the interaction of the fusion protein with
the intestine, we obtained 8μm of frozen gut sections of
NOD mice from the protein binding assay. Photomicro-
graphs showed that the GFP tag was eﬀectively located on
the fusion proteins similarly to other tagged probes or anti-
bodies, as expected (Figure 6). We concluded that the fusion
GFP-tagged proteins had complete GFP ability and could be
used to trace the process of protein transportation in the
intestinal mucosa by direct visualization of the GFP tag.
3.6. Feeding with CTB-Ins-GFP Fusion Protein Induced a
Humoral Immune Response. Generally, oral administration
of certain protein antigens can induce humoral immunore-
actions to the antigen, so we assayed 10-week-old female
NOD mouse anti-CTB and anti-insulin antibody serum
titers to investigate whether feeding Saline (group 1), CTB-
GFP(group2),CTB-Ins-GFP(group3),orCTB-INS(group
4) hemolymph would induce speciﬁc humoral immune
responses. We found that NOD mice fed CTB-Ins-GFP
or CTB-INS hemolymph had both anti-CTB and anti-
insulin antibodies in their sera (data not shown). Serum
anti-CTB IgG1 levels in animals fed CTB-GFP, CTB-Ins-
GFP, or CTB-INS hemolymph were signiﬁcantly higher than
in the Saline group (antibody titer: 758 ± 140, 734 ±
133, and 812 ± 150 versus 79 ± 18, resp.; n = 9p e r8 Clinical and Developmental Immunology
Table 2: Treg cell proportion in the peripheral lymph tissues of NOD mice.
Type of mice Material oral administrated
CD4+CD25+Foxp3+ Tc e l l ’ sp r o p o r t i o n( % )
Nondiabetes Diabetes
Spleen Lymph node Blood Spleen Lymph node Blood
NOD mice
Saline 1.45 ± 0.38 1.82 ± 0.36 2.22 ± 0.14
5.42 ± 0.83 8.11 ± 1.6 20.63 ± 5.79 CTB-GFP 1.54 ± 0.42 1.93 ± 0.29 2.19 ± 0.2
CTB-Ins-GFP 2.75 ± 0.34∗ 2.9 ± 0.42∗ 3.61 ± 0.70∗
CTB-INS 2.87 ± 0.35∗∗∗∗ 3.16 ± 0.53∗ 3.71 ± 0.78∗
Normal mice 0.89 ± 0.11 ± 0.28 1.5 ± 0.36
Splenocyte (1 × 105 cells) isolated from CTB-INS, CTB-Ins-GFP, CTB-GFP, Saline-fed NOD mice at 10 weeks of age were treated with the mouse regulatory
T cell staining kit by the protocol. Splenocytes of the normal mice and the diabetic NOD mice (from the diabetes onset experiment) was used as contrasts.
These treated splenocytes were examined by FACScan ﬂow cytometer for CD4+CD25+Foxp3+ Treg cell proportions. Results are presented as the mean titer
values ± S.D. Four mice per group were tested in two separate experiments.
∗Values P<. 05 is for statistical diﬀerences among mice groups treated with CTB-INS, CTB-Ins-GFP, CTB-GFP, and Saline.
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Figure 5: Eﬀect of fusion protein feeding on diabetes development.
Five-week-old female NOD mice were fed CTB-INS (group 1,
n = 18, black), CTB-Ins-GFP (group 2, n = 18, red), CTB-GFP
(group 3, n = 18, green), or Saline (group 4, n = 10, blue) four
times per week until 38 weeks of age. Diabetes was conﬁrmed by
hyperglycemia (>16.7mM glucose) for 2 consecutive weeks. The
ANOVAtestrevealed asigniﬁcantreductioninT1Donsetingroups
1 and 2 compared with groups 3 and 4 (P = .0276). No signiﬁcant
diﬀerence was found between group 1 and group 2 (P = .9683).
group; P<. 05). A signiﬁcant increase in serum IgG1
anti-insulin antibody titers in NOD mice fed CTB-Ins-GFP
or CTB-INS hemolymph was observed compared with the
CTB-GFP and Saline groups (antibody titer: 523 ± 109 and
581 ± 96 versus 73 ± 34 and 88 ± 39, resp.; n = 9p e r
group; P<. 05), with no signiﬁcant diﬀerence in serum
IgG2a antibodies (Figure 7(a)). Additionally, IgA antibodies,
rather than IgE, in the sera of groups 2–4 were elevated in
contrast to group 1 (antibody titer: 126 ± 28, 133 ± 29,
and 154 ± 39 versus 20 ± 6, resp.; n = 9p e rg r o u p ;P<
.05; Figure 7(b)). These ﬁndings indicate that oral insulin-
induced Th2 lymphocyte-mediated oral tolerance resulted in
predominantly IgG1 rather than other antibody isotypes.
3.7. Upregulation of Treg Cells in the Spleen, Intestinal Lymph
Nodes, and Blood. We assayed the CD4+CD25+Foxp3+ T
cells in the peripheral lymph tissues of 10-week-old female
NOD mice by FACScan ﬂow cytometry. The results showed
that the proportions in CTB-INS and CTB-Ins-GFP fed
NOD mice were signiﬁcantly elevated in contrast to the
CTB-GFP and Saline groups (2.87 ± 0.35% and 2.75 ±
0.34% versus 1.54 ± 0.42% and 1.45 ± 0.38%, resp., in
the spleen, 3.16 ± 0.53% and 2.9 ± 0.42% versus 1.93 ±
0.29% and 1.82 ± 0.36%, resp., in intestinal lymph nodes,
and 3.71 ± 0.78% and 3.61 ± 0.7% versus 2.19 ± 0.27%
and 2.22 ± 0.14%, resp., in blood, P<. 05; Table 2),
which were correlated with the suppression of T1D onset,
and all were higher than in normal mice (0.89 ± 0.11%,
1.01 ± 0.28%, and 1.5 ± 0.36% in the spleen, intestinal
lymph nodes, and blood, resp.). However, in diabetic NOD
mice, the CD4+CD25+Foxp3+ T cell proportions were much
higher than that in any other group (5.42 ± 0.83%, 8.11 ±
1.6%, 20.63 ± 5.79% in the spleen, intestinal lymph nodes,
and blood, resp., P<. 05), and we believe that this was
a result of a T1D autoimmune feedback mechanism. The
results indicated that the induced oral tolerance speciﬁcally
increased the proportions of CD4+CD25+Foxp3+ T cells,
which might suppress T1D progression in the peripheral
lymph system.
3.8. Eﬀect on Spleen Lymphocytes. To demonstrate the puta-
tivesuppressiveregulatoryeﬀectofinducedTreg(iTreg)cells,
we determined the proliferative and migratory abilities of
spleen cells in treated NOD mice in vitro by BrdU label
analysis and a Transwell assay. The performances indicated
that speciﬁc immune suppression existed in the CTB-INS-
and CTB-Ins-GFP- treated NOD mice, manifested by the
suppression of the ability of the cells to proliferate and
migrate (proliferative ability: CTB-INS- and CTB-Ins-GFP-
treated groups: 60.19 ± 6.51% and 59.1 ± 5.38%, resp.,
P = .00074, versus CTB-GFP and Saline treated groups or
normal mice 67.87 ± 4.13%, 69.11 ± 3.6%, and 71.67 ±
6.73%, resp., P = .00009; migratory ability: CTB-INS and
CTB-Ins-GFP- treated groups: 128 ± 8 and 115 ± 9, resp.,
P = .025, versus CTB-GFP- and Saline-treated groups or
normal mice: 200 ± 17, 191 ± 11, and 182 ± 28, resp.,
P = .0068; Figure 8). This suggests that oral tolerance mightClinical and Developmental Immunology 9
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Figure 6: Intestinal mucosal binding assay. Images of the NOD mice frozen gut sections of (a)NOD mice fed CTB-GFP and (b) NOD mice
fed CTB-Ins-GFP. Gut sections under (1) normal light, (2) blue light, and (3) overlapped. Magniﬁcation is 40x.
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Figure 7: Serum antibody assay of treated NOD mice. (a) Anti-CTB IgG1, anti-insulin IgG1, and IgG2a serum antibody titers and (b) IgA
and IgE serum titers in mice fed CTB-INS, CTB-Ins-GFP, CTB-GFP, or Saline. Results are presented as the mean titer values ± SD. Four or
ﬁve mice per group were individually tested in two separate experiments.
suppress spleen lymphocyte activity via the iTreg cells in
some way.
3.9. Adoptive Transfer of Treatment Regulatory Cells. To
determine whether administration of the CTB-Ins-GFP
protein protected NOD animals from the development of
diabetes via some regulatory cells, we used an adoptive
transfer model. Splenocytes from 10-week-old CTB-INS-
(group 1), CTB-Ins-GFP- (group 2), and CTB-GFP (group
3)-fed NOD mice were mixed with diabetogenic splenocytes
and given i.v. to 6–8-week-old syngeneic NOD/SCID
recipient mice. Mice receiving only diabetogenic splenocytes10 Clinical and Developmental Immunology
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Figure8:ProliferationandmigrationabilitiesofsplenocytesintreatedNODmice.Splenocytes(1 ×107 cells)isolatedfromCTB-INS-,CTB-
Ins-GFP-, CTB-GFP-, Saline-fed and normal mice at 10 weeks of age were cultured in 24-well plates with 10μM BrdU for 24h. Cells were
immunohistochemically stained and examined for stained cell proportions (representative of proliferative ability) according to the protocol.
Orsplenocytes wereculturedintheupperchamber ofTranswellplates with0.6mLofnormalculturemedium(IL2150IU/mL)placed inthe
bottom chamber at 37◦C with 5% CO2 for 14h. The migrated cells were ﬁxed, stained, and numbered under the microscope. A. Splenocyte
BrdU assay. Magniﬁcation is 400x. (b) Splenocyte Transwell assay. The magniﬁcation is 400x. (c) Statistical analysis of proliferative ability.
(d) Statistical analysis of migratory ability. All results are presented as the mean titer values ± S D .F i v em i c ep e rg r o u pw e r et e s t e di nt w o
separate experiments.
(group 4) were used as a negative control. We found 83%
and 100% (5/6 and 6/6) of the NOD/SCID recipient mice
receiving splenocytes from group 3 and group 4 NOD
mice, respectively, developed diabetes, whereas splenocytes
from group 1 and group 2 NOD mice were able to prevent
diabetes in 67% and 50% (4/6 and 3/6) of NOD/SCID mice,
respectively (groups 1 and 2 versus groups 3 and 4, P =
.0001; group 3 versus group 4, P = .6064; Figure 9). These
results demonstrated that oral administration of CTB-INS
or CTB-Ins-GFP fusion proteins generated some regulatory
cells, including increased CD4+CD25+Foxp3+ Treg cells,
which could transfer suppressive ability in NOD mice.
4. Discussion
Oral tolerance is a potential therapeutic strategy, because it
can induce “inappropriate” immune responses to speciﬁc
“ s e l f ”a n t i g e np r o t e i n st h a tp r e c e d eo v e r ta u t o i m m u n e
d i s e a s e ,s u c ha sT 1 D[ 1]. Human insulin is the major
autoantigen orally administered in treating T1D via induc-
tion of special mucosal tolerance [6, 11, 19]. However, the
obvious eﬀect and application of this approach depends not
onlyontheavailabilityofautoantigensproducedinquantity,
but also on the detailed mechanisms of tolerance to make it
amenable to clinical testing.Clinical and Developmental Immunology 11
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Figure 9: Splenocytes from insulin-fed NOD mice prevented
diabetes after adoptive transfer. Splenocytes (1 × 107 cells) isolated
fromCTB-INS-(group1,black),CTB-Ins-GFP-(group2,red),and
CTB-GFP- (group 3, green) fed mice at 10 weeks of age were mixed
with diabetogenic splenocytes (1 × 107 cells) from diabetic NOD
mice,andthencotransferredto8-week-oldNOD/SCIDmice(n = 6
for all four groups) with a diabetogenic splenocyte-only injection
(group 4, blue) as a control. The development of diabetes in the
recipients was monitored for 15 weeks. The ANOVA test revealed a
signiﬁcantreductioninT1Donsetingroups1and2comparedwith
groups 3 and 4 (P = .0001). No signiﬁcant diﬀerence was found
between groups 3 and 4 (P = .6064).
Repeated oral administration of large doses of insulin is
essential in maintaining speciﬁc unresponsiveness for long
periods because of the large absorptive intestinal mucosal
area. The CTB peptide as a mucosal carrier was applied
successfully to induce peripheral immunological tolerance
[7, 11]. In previous studies, it was shown that speciﬁc
tolerance could be enhanced by conjugating insulin to the
CTB peptide [19]. The CTB-conjugated protein functions
in a pentameric structure, interacting with GM1 ganglioside
expressed on the intestinal epithelial cells, facilitating the
mucosal immune reaction and increasing the autoantigen
concentration. Others have reported that CTB may enhance
theimmunereactionbyaﬀectingtheintestinaltightjunction
[24]. Moreover, Terahara et al. [13] found that orally
administered CT induced villous M-like cells in mice.
Comprehensive gene expression revealed that they share
traits with both intestinal epithelial cells and PP M-cells.
The latter play signiﬁcant roles in mucosal immunity. In
a previous study of T1D treatment in NOD mice by oral
insulin, Zhang et al. [6] found that administration of 1mg
of porcine insulin was an eﬀective oral dose. However, we
were able to decrease the eﬀective dose of the autoantigen
in the active CTB pentameric form to about 50μg. Together,
our data and the results from other researchers support
the theory that low doses administrated for oral tolerance
favor active suppression, whereas high doses favor clonal
anergy/deletion [25, 26].
So far, CTB-based fusion proteins have been successfully
achieved in E. coli [8], potatoes [27], tomatoes [28], tobacco
[9], and even rice [10]. In this study, we used silkworm to
express the fusion proteins by insect BES. The insect BES
was ﬁrst used in 1993 to obtain the cytokine interferon-α
and has been broadly applied to produce proteins due to its
numerous virtues [20]. In recent years, the improved BES,
the so-called Bac-to-Bac BES, has been used more, because
it is quicker, more eﬃcient, and allows easier identiﬁcation
withlowerworkloads[29].Inthepresentstudy,weproduced
protein at levels up to 0.58mg/mL. Additionally, the pro-
teinase inhibitors [30] and biocapsule-like fat of silkworms
may keep the protein of interest stable and protect it
againstgastrointestinaldegradation,makingthehemolymph
especially appropriate for oral administration. The results
indicate that Bac-to-Bac BES is suitable for producing the
large quantities of proteins or polypeptides of interest.
The precise mechanism by which the CTB-Ins-GFP
fusion protein enhances oral tolerance remains unclear. As a
popular ﬂuorescentprotein ﬁrstdiscovered in 1962, GFP was
expressed in E. coli to reveal that FimH+ bacteria combine
glycoprotein 2 of the intestinal M-cells to initiate a mucosal
immune response [14]. It was also useful in work on the
localization, structure, and dynamic processes of molecules,
cells, and organisms, such as viruses, and even in interaction
studies among DNA, RNA, and proteins [31, 32]. In the
present study, the fusion protein was shown to interact with
the gut mucosa, but appeared in neither the spleen nor
the intestinal lymph nodes (data not shown). The orally
administered protein has a low bioavailability, less than 3.1%
[33]. It was previously reported that low amounts of insulin
induced regulatory CD4+ T-cells [34–36]. In other diseases,
like the arthritis mouse model, orally administered type II
collagen was shown to induce CD4+CD25+Foxp3+ regula-
torycellsbyIDOexpressingCD11c+ DCsinintestinalPeyer’s
patches in the treatment of arthritis [37–39]. Moreover, oral
tolerance induced by OVA coupled to CTB promoting OVA
speciﬁc regulatory CD4+CD25+Foxp3+ T-cells was depen-
dent on B lymphocytes not only in the mucosal inductive
draining lymph node but also at the inﬂamed eﬀector sites
to suppress eﬀector T-cells [16, 40, 41]. It was also observed
that the expression of CD86 in B-cells decreased, whereas IL-
10producingCD19+ B-cellssimultaneouslyincreased.These
Treg cells were reported to induce other CD4+ cells into
becoming suppressors in addition to inducing the apoptosis
or depletion of eﬀector T-cells by contact-dependent or
cytokine-dependent action mechanisms. According with
this, our results indicate that CTB enhances immunomod-
ulation of insulin by the humoral and Th2-like immune
responses and induction of CD4+CD25+Foxp3+ regulatory
T cells. The adoptive cotransfer experiment also showed that
the regulatory cells were functionally active. This is probably
because the autoantigen insulin plays an important role in T
cell diﬀerentiation into Treg cell lineages. Administration of
exogenous CTB-Ins-GFP fusion protein may create a special
microenvironment in the gut that can promote beneﬁcial
humoral Th2-like immune responses, instead of harmful
Th1-likeimmunereactions[42–44],andalsoinsulin-speciﬁc
regulatory T cells by some immature DCs or special B12 Clinical and Developmental Immunology
cells in the intestine, which play an essential role in the
development of spleen cells [45]. Although the exact process
by which the protein treats T1D remains to be discovered,
these ﬁndings validate the use of the autoantigen insulin as
anideal immunotherapy strategyin the treatmentof diseases
involving CD4+CD25+Foxp3+ Treg cells.
Treg cells are attracting great interest because of their
potential therapeutic role in autoimmune diseases [46]. To
some extent, T1D can be “cured” by pancreatic transplan-
tation [47], gene therapy [48, 49], or injection of speciﬁc
autoantibodies, such as anti-CD3 antibodies [50]. However,
none of these meet the requirements of an ideal cure [51].
Our work oﬀers support for the use of oral tolerance in treat-
ing T1D. Generally, our data and other studies suggest that
the antigen amount, delivery mode, and/or coadministered
adjuvant molecules may have profound eﬀects on directing
the mechanism of tolerance. Successful application of oral
tolerance in the treatment of human diseases will depend
not only on the detailed functional mechanisms but also
on strategies that can improve antigen presentation, alter
the administered dose and formulations, use potent mucosal
adjuvants,targetthecorrectcellsinthegut-liveraxis,develop
immune biomarkers for detecting eﬀects, use combination
therapies with other immunomodulatory agents, and target
the right patient populations [52–55].
5. Conclusions
In summary, this study demonstrates that low doses of
orally administered silkworm-produced CTB-Ins-GFP pro-
tein can eﬀectively suppress the development of diabetes in
NOD mice, where the treatment function involves inducing
CD4+CD25+Foxp3+ Treg cells. Our experimental evidence
lends further support to the hypothesis that orally adminis-
teringtheCTB-InsproteinmaybeafeasiblewaytotreatT1D
patients, and oral tolerance may be a powerful therapeutic
strategy for treating autoimmune diseases.
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